Interferon-gamma and urine neopterin in attacks of the hyperimmunoglobulinaemia D and periodic fever syndrome by Drenth, J.P.H. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
This full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/14919
 
 
 
Please be advised that this information was generated on 2014-11-11 and may be subject to
change.
European Journal o f  Clinical Investigation  (1995) 25, 6 8 3-686
Interferon-7 and urine neopterin in attacks of the 
hyperimmunoglobulinaemia D and periodic fever 
syndrome
J. P. H. D R E N T H ,*  R. J. PO W E L L ,t N . S. B R O W N f & J. W. M. V A N  D E R  M EER* ^Department o f  
Medicine, Division o f  General Internal Medicine, University Hospital St Radboud, Nijmegen, the Netherlands; 
tD epartm ent o f  Imm unology and {Department o f  Clinical Chemistry, University Hospital, Queens Medical 
Centre, Nottingham , U K
Abstract. The hyperimmunoglobulinaemia D  and per­
iodic fever (hyper-IgD) syndrome is typified by recur­
rent unpredictable febrile attacks with abdominal 
pain, joint involvement (arthralgias/arthritis), head­
ache, skin lesions and a polyclonal elevation o f  serum 
IgD ( > 100 U m L  ]). Interferon-gamma (IF N -7 ) is a 
major proinflammatory cytokine which could play a 
role in the pathogenesis o f  the attacks. There is a need 
for parameters (if possible non-invasive) to monitor  
disease activity. A potential candidate is neopterin 
which is released by monocytes/m acrophages when  
stimulated with IF N -7 , excreted unchanged in urine, 
and appears to be an early and sensitive marker for 
activation o f  the immune system. We measured rectal 
body temperature, serum IF N -7 , and urine neopterin 
in 10 hyper-IgD patients both during and between 
attacks. The body temperature rose to a mean o f  
38-9°C on the first day o f  the attack and normalized  
within 5 days. Serum IF N - 7  during the first day o f  the 
attack was 2-98 I U m L “ 1 and was significantly lower 
during remissions. The urine neopterin excretion was 
268 ±  170 ¿¿m olm oP 1 creatinine between attacks and 
was significantly increased to 638 =L 275 ¿¿m olm oP 1 
creatinine on the first day o f  symptoms. Maximal 
urine neopterin values were reached on the fourth 
day o f  the attack (1051 ±  387 / im o lm o l” 1 creatinine) 
and excretion gradually declined and attained values 
below 400 p m o \  mol 1 creatinine after 9 days. There 
was a good correlation between serum IF N - 7  and 
urine neopterin. The increases in serum IF N - 7  and 
urine neopterin suggest activation o f  the cellular 
immunity during the febrile attacks o f  the hyper-IgD  
syndrome. Furthermore, the activation o f  the cellular 
immune system appears to persist several days after 
normalization o f  the body temperature. The signifi­
cant correlation between I F N - 7  and urine neopterin in
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the hyper-IgD syndrome accords with experimental 
data suggesting that IF N - 7  is the dominant factor in 
the release o f  neopterin. Our study shows that urinary 
neopterin is a good quantitative and qualitative para­
meter to monitor disease activity in patients with the 
hyper-IgD syndrome
Keywords. Hyper-IgD syndrome, interferon-gamma, 
urine neopterin.
Introduction
The hyperimmunoglobulinaemia D  and periodic fever 
syndrome (hyper-IgD) is characterized by recurrent 
attacks o f  fever associated with persistently elevated 
polyclonal serum IgD levels ( >  100 U m L -1 ). [1] An  
autosomal recessive inheritance is typical [2]. Symp­
toms commence at an early age and persist through­
out life and the febrile attacks occur every 4 - 8  weeks, 
lasting 3 - 7  days. During these episodes the patients 
may suffer from abdominal distress (vomiting, 
diarrhoea and pain), skin lesions, joint involvement, 
headache and lymphadenopathy [3,4]. The cause o f  
the syndrome is unknown but since attacks are 
featured by an important inflammatory reaction, 
IF N - 7  as a major proinflammatory cytokine could  
play a role in the pathogenesis. Therefore, we 
measured IF N - 7  as well as neopterin, a pteridine 
derivative, which is released by m onocytes/m acro­
phages when stimulated with I F N - 7  [5]. Neopterin, 
is conveniently excreted in urine and can be measured 
easily. It appears to be an early and sensitive marker 
o f  activation o f  the immune system [6 ]. In inflamma­
tory diseases such as rheumatoid arthritis and sys­
temic lupus erythematosus urinary neopterin levels 
correlate closely with the disease activity [7,8]. The 
present study investigates whether I F N - 7  and urine 
neopterin are increased during the febrile attacks o f  
the hyper-IgD syndrome and assesses the clinical
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Days after onset attack
Figure 1. The rectal body temperature in 10 patients in the first days after onset of an attack. Data are expressed as mean and 
standard deviation of mean. There is a normalization of the body temperature 5 days after the start of the attack.
utility o f  urinary neopterin as marker o f  disease 
activity in these patients.
Patients and methods
Patients
Ten patients, six female and four male, with the hyper- 
IgD syndrome were included in the study and the 
diagnosis o f  hyper-IgD syndrome was made accord­
ing to standard criteria [3]. The mean age at time o f  
sampling was 28*8 years (range 8-61  years). Patients 
were instructed to commence sampling on the first day 
o f  the attack and to continue until the fever had 
subsided, with a maximum o f  10  days sampling. 
Each day the first morning urine specimen was 
sampled in a special container, shielded from light, 
and frozen at -2 0 °C  until analysis. The rectal body  
temperature was measured daily, using a digital ther­
mometer. Samples for urine neopterin concentrations 
were obtained in each patient between attacks to 
give baseline values. Sampling o f  serum for I F N - 7  
measurements was performed on the first day o f  the 
attack and during remission.
Laboratory  measurements
The IF N - 7  concentration was determined by a com ­
mercially available immunoradiometric assay. (Med- 
genix, Amersfoort, the Netherlands). The microtitre 
plate wells are coated with monoclonal anti IF N -7 .1 ^  n
After washing, radiolabelled ( I) anti-IFN - 7  was 
added. Bound radioactivity was determined in a 
gamma counter and the I F N - 7  concentrations were 
calculated from standard curves. The lower limit o f  
detection o f  the assay was 0-2 I U m L -1 . The mean 
value obtained in healthy controls is 0-55 ±  0T 4  
I U m L -1  (manufacturer’s information).
Determination o f  neopterin was by reversed-phase
high-performance liquid chromatography with minor 
modifications [9]. Briefly, urine samples were centri­
fuged to remove debris, diluted in 1 to 10  with water 
containing dimethylpterine as an internal standard 
and injected directly onto a Techsphere 5 O D S  
column (HPLC Technology Ltd). A binary gradient 
elution was used with an initial mobile phase o f  2 % 
methanol in 15 m m o lL -1  phosphate buffer, pH 6-4, 
increasing to 25% methanol after 12min, and creati­
nine was detected separately using a kinetic alkaline 
picrate (Jaffe) method. The ratio o f  neopterin to 
creatinine was calculated to compensate for variations 
o f  urine density. The median urine neopterin value for 
a group o f  65 healthy controls was 149 /imol m ol -1  
creatinine (range 62 -2 7 3 )  [8 ].
Statistical analysis
The paired non-parametric W ilcoxon test was used 
for statistical comparison o f  values obtained during 
active disease compared to remission values. Prob­
ability (P) values were calculated on the basis o f  two- 
tailed tests. A correlation coefficient was calculated 
with the Pearson’s correlation test. A P  value o f  
<0-05  considered to be the lowest level o f  signifi­
cance. Data are given in mean ±  standard deviation.
Results
The attacks in the hyper-IgD were featured by an 
increase o f  the mean body temperature to 38 9°C on 
the first day o f  the attack which returned to normal by 
day 5 (Fig. 1).
Serum for IF N - 7  measurements was obtained from 
nine patients during an attack. The IF N - 7  concentra­
tion during the first day o f  the attack was 2-98 ±  3*55 
(median 1*33) I U m L -1  and was significantly lower, 
0-59 ±  0-39 (median 0-44) IU m L -1  during remissions 
(Fig. 2). For 10 hyper-IgD patients a total 69 urine
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Figure 2. The left panel refers to the individual concentrations of circulating IFN -7  in nine patients during and in between 
attacks of the hyper-IgD syndrome. The mean and standard error of the mean are displayed at either side. IFN -7  
concentrations were significantly higher during active disease compared to remission (P < 0-05). The right panel indicates 
the individual urine neopterin values for 10 patients between and during attacks of the hyper-IgD syndrome. The mean and 
standard error of the mean are displayed at either side. Note the significant elevation of urine neopterin during attacks 
(P = 0-002).
samples (mean 6*9 per patient) were collected during 
attacks. Three patients collected the complete set o f  
urine samples for the 10 days. The control urine 
neopterin excretion for the 10  patients was 268 ±  
170 (median 199) /imol m ol - 1  creatinine, significantly 
lower than values obtained on the first day o f  symp­
toms: 638 =t 275 (median 604) ¿ /m olm ol -1  creatinine 
(Fig. 2) (P  =  0-002). All patients had higher total 
urine neopterin during attacks compared to between  
attacks. The mean urine neopterin increased in the 
first days o f  the attack and maximal values were 
reached on the fourth day o f  the attack (1051 ±  
387 ¿miol m ol -1  creatinine). The urine neopterin 
gradually declined and attained values below  
4 0 0 ^ m o lm o l_1 creatinine after 9 days (Fig. 3). One 
patient started sampling 2  days before the onset o f  the 
febrile attack. In the days preceeding the attack 
neopterin excretion values were 245 and 
2 8 0 / im o lm o l-1 creatinine. The excretion increased 
respectively to 345 and 780 ¿im olm ol -1  creatinine 
on the first 2 days o f  the febrile attack. There was a 
good correlation between serum IF N - 7  and urine 
neopterin excretion: r =  0-6675 (P  < 0-05). The 
decrease in body temperature and thus the end o f  an 
attack, anticipated the decrease o f  urine neopterin by 
4 - 5  days. In five patients the activation o f  the cellular 
immune system (urine neopterin > 2 0 0  / im o lm o l - 1  
creatinine) persisted during remission despite 
apparent clinical well-being.
Discussion
Serum concentrations o f  IF N - 7  and urine excretion o f  
neopterin correlated well with the clinical condition o f
the hyper-IgD patients. IF N - 7  increased fivefold over 
remission values during active disease. IF N - 7  partici­
pates in the human inflammatory response, partly 
through its ability to induce production o f  T N F a  
and other cytokines [10]. IF N - 7  itself may be a 
pyrogenic com pound, but its presence does not 
explain all signs and symptoms in the hyper-IgD  
syndrome [11]. Other proinflammatory cytokines pos­
sibly involved in the pathogenesis are currently being 
studied by us. We found that urine neopterin values 
are low between attacks o f  the hyper-IgD syndrome 
but increase significantly during attacks. Neopterin is
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Figure 3. Urine neopterin in fimo\ mol- 1  creatinine ratios during the 
first 10 days of an attack in 10 patients with the hyper-IgD 
syndrome. Day 1 denotes the first day of the attack as defined by 
the symptoms. Data are expressed as mean and standard deviation.
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a non-specific marker o f  cellular activation being 
produced by human macrophages in response to 
IF N - 7  [5]. Neopterin is a stable compound, readily 
detectable and easy to measure. Since neopterin is not 
metabolized, the urine excretion reflects the integrated 
release o f  neopterin [12]. Furthermore, serum IF N - 7  
and urine neopterin correlate significantly in the 
hyper-IgD syndrome which is in line with these 
experimental data in vitro suggesting that IF N - 7  is 
the dominant factor involved in the release o f  neop­
terin [5]. The course o f  the urine neopterin excretion 
during the attacks demonstrates that maximal values 
are attained within 4 days. Data from one patient 
indicate that neopterin excretion values are normal in 
the days immediately before an attack. This may 
suggest that the value o f  neopterin as a predictor o f  
attacks is rather limited. The end o f  the attack, as 
indicated by the normalization o f  the rectal body  
temperature and disappearance o f  the symptoms  
occurs in 5 days, but at the same time urine neopterin 
still continued to be elevated above individual refer­
ence values. Thus, the activation o f  the cellular 
immune system appears to persist after normalization  
o f  the temperature.
Our study shows that urinary neopterin is a good  
quantitative and qualitative parameter to monitor  
disease activity in patients with the hyper-IgD syn­
drome. A reliable non-invasive parameter is needed in 
the management o f  the hyper-IgD syndrome because 
many patients are young ( < 10  years), and because o f  
the outpatient basis o f  the treatment. Moreover, 
evaluation o f  drugs in a disorder characterized by 
unpredictable febrile attacks requires a dependable 
parameter. In studies evaluating the effect o f  colchi­
cine in familial Mediterranean fever, another periodic 
fever syndrome, patients were requested to keep 
records o f  their attacks with symptom diaries and/or  
postcards (to be sent to the investigators when having 
an attack) [13-15]. Symptom diaries depend to a large 
extent on self-interpretation by the patient and con­
sequently more objective and accurate parameters are 
clearly needed. The use o f  urine neopterin to monitor  
disease activity has great advantages; the patients can 
sample and store urine at home in their home freezer 
for up to 6  months contrasting with serum that 
requires processing.
In conclusion, urine neopterin appears to be a good  
monitor o f  disease activity in the hyper-IgD syn­
drome. Neopterin measurements can be useful when 
evaluating the effect o f  therapy for the hyper-IgD  
syndrome. Our data suggest that attacks o f  the 
hyper-IgD syndrome are associated with macrophage  
activation as evidenced by increased serum IF N - 7  and 
urine neopterin excretion.
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